IRVINE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a ...
– Announced positive initial comparative analytical results, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX ® – – Reported positive FDA BPD Type 2a ...
– Announced topline results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the preventive treatment of episodic migraine that support advancing the program into a pivotal Phase 3 study – – ...
Veteran biotechnology leader with extensive capital markets experience joins AEON as Company advances lead asset through key regulatory milestones IRVINE, Calif., March 09, 2026 (GLOBE NEWSWIRE)-- ...
– Reported positive FDA BPD Type 2a meeting, with FDA feedback providing a clear framework for advancing the comparative analytical plan for ABP-450 biosimilar program – – Strengthened balance sheet ...
Bencich, 49, previously worked as chief executive of Achieve Life Sciences from September 2020 to August 2024. He was chief operating officer of Achieve for three years before that. Aeon said Monday ...
IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE)-- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results